{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:45:29Z","timestamp":1791827129969,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmc.2026.118818","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:32:37Z","timestamp":1791387157000},"page":"118818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of dihydroquinolizinone (DHQ)-based inhibitors for suppression of hepatitis B viral infections"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7946-7402","authenticated-orcid":false,"given":"Yu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8051-6216","authenticated-orcid":false,"given":"Zhidong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3586-4322","authenticated-orcid":false,"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-457X","authenticated-orcid":false,"given":"Honggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8799","authenticated-orcid":false,"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3479-3650","authenticated-orcid":false,"given":"Guanghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0719-8991","authenticated-orcid":false,"given":"Chuanwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4302-9448","authenticated-orcid":false,"given":"Jiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-730X","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmc.2026.118818_bb0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s42770-023-00970-y","article-title":"Hepatitis B virus-induced hepatocellular carcinoma: a persistent global problem","volume":"54","author":"Boora","year":"2023","journal-title":"Braz J Microbiol"},{"issue":"9959","key":"10.1016\/j.bmc.2026.118818_bb0010","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bmc.2026.118818_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/genes10040260","article-title":"Meeting the challenge of eliminating chronic hepatitis B infection","volume":"10","author":"Revill","year":"2019","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.bmc.2026.118818_bb0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus infection","volume":"7","author":"Vaillant","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"3","key":"10.1016\/j.bmc.2026.118818_bb0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference(\u2021)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2026.118818_bb0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2026.118818_bb0035","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1053\/j.gastro.2019.01.019","article-title":"Factors associated with rates of HBsAg Seroclearance in adults with chronic HBV infection: a systematic review and Meta-analysis","volume":"156","author":"CME exam 3","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bmc.2026.118818_bb0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","article-title":"Effect of Pegylated interferon plus Tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience","volume":"43","author":"Hu","year":"2021","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.bmc.2026.118818_bb0045","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i4.105797","article-title":"Drug development for chronic hepatitis B functional cure: recent progress","volume":"17","author":"Liu","year":"2025","journal-title":"World J Hepatol"},{"key":"10.1016\/j.bmc.2026.118818_bb0050","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.8b01245","article-title":"Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action","volume":"61","author":"Han","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118818_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105407","article-title":"Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitor","volume":"141","author":"Bopst","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.bmc.2026.118818_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/acs.jmedchem.3c01981","article-title":"Structure\u2212activity relationships and discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2\u2212h][1,7]naphthyridine-9-carboxylic acid (AB-452), a novel orally available HBV RNA destabilizer","volume":"67","author":"Gotchev","year":"2024","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118818_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/toxsci\/kfac009","article-title":"Neurotoxicity of an hepatitis B virus (HBV) transcript inhibitor in 13-week rat and monkey studies","volume":"186","author":"Lake","year":"2022","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.bmc.2026.118818_bb0070","unstructured":"Mammoliti, O.; Palisse, A.; Blieck, A. D.; Joannesse, C.; Allart, B.; Laruelle, C.; Jaunet, A.; Munck, T. D.; Van der Plas, S.; Duthion, B.; Catana, C.; Christophe, T.; Houvenaghel, N.; Porte, V.; Jimenez, J. M.; Beirinckx, F.; Iwens, A.; Chypre, M.; De Rijck, K.; Vandervoort, N.; Nelles, L."},{"issue":"3","key":"10.1016\/j.bmc.2026.118818_bb0075","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/acs.jmedchem.5c01703","article-title":"Discovery and characterization of GLPG3808, a PAPD5\/7 inhibitor for suppression of hepatitis B viral infections","volume":"69","author":"Cl\u00e9ment-Lacroix","year":"2026","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118818_bb0080","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/acs.jmedchem.5c01704","article-title":"HBsAg suppression by a new series of HBV RNA destabilizers: discovery and effects on in vitro neurite outgrowth","volume":"69","author":"Huck","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118818_bb0085","series-title":"Functionalized heterocycles as antiviralagents","author":"Panarese","year":"2020"},{"key":"10.1016\/j.bmc.2026.118818_bb0090","series-title":"Compounds for the treatment of hepatitis B virus infection","author":"Aktoudianakis","year":"2018"},{"key":"10.1016\/j.bmc.2026.118818_bb0095","doi-asserted-by":"crossref","first-page":"20467","DOI":"10.1021\/acs.jmedchem.4c01928","article-title":"Structure\u2212activity relationships and discovery of (S)-5-(tert-butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2\u2032,1\u2032,2,3]imidazo[4,5-h]quinoline-3-carboxylic acid (AB-161), a novel orally available and liver-centric HBV RNA destabilizer","volume":"67","author":"Gotchev","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118818_bb0110","author":"Randomized"},{"key":"10.1016\/j.bmc.2026.118818_bb0115","series-title":"Fused tetracyclic compounds and uses thereof in medicine","author":"Huang","year":"2020"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:54:20Z","timestamp":1791824060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":21,"alternative-id":["S0968089626002749"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118818","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of dihydroquinolizinone (DHQ)-based inhibitors for suppression of hepatitis B viral infections","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118818"}}